← Eichor
Study identifier: NCT05424692 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

Condition: Colon Cancer · Rectal Cancer · Chemotherapy Effect  ·  Sponsor: Peking Union Medical College Hospital

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.

This description comes directly from the study's public registry record.

Talk to the study team

Guole Lin  ·  13801081483  ·  linguole@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05424692